Scilex
Scilex's revenue fell 46.5% to $30 million in fiscal 2025. Its operating margin was −1,143.7%, down from −147.4% a year earlier. Free cash flow was $4 million, down 81.0%. The diluted share count rose 108662.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Scilex lost money in fiscal 2025: a net loss of $374 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 5 | 2 | 4 | 3 | 5 |
| Debt incl. finance leases | 110 | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | 105 | −2 | −4 | −3 | −5 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | 0.0x | — | — | — |
| Interest coverage | −3.0x | −5.3x | −98.7x | −42.5x | −30.2x |
| Current ratio | 0.1x | 0.7x | 0.2x | 0.2x | 0.1x |
| Quick ratio | 0.1x | 0.6x | 0.2x | 0.1x | 0.1x |
Cash flow
Projections
Project Scilex's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Scilex shares on the open market, and 1 insider sold $12.8 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 30, 2025 | Scilex Holding Co10% owner | Sold | 9,657,300 | $0.54 | $5.2 million | Form 4 |
| Dec 29, 2025 | Scilex Holding Co10% owner | Sold | 7,310,984 | $0.66 | $4.8 million | Form 4 |
| Dec 26, 2025 | Scilex Holding Co10% owner | Sold | 3,689,016 | $0.75 | $2.8 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 6 of 9 | 3 of 9 |
| Rule of 40 | −21.5% | 55.3% | −34.4% |
| Altman Z'' | −36.61 | −41.88 | −22.99 |
| Accruals ratio | −99.7% | −94.9% | −165.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Pass | Pass | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 3 of 9 | 6 of 9 | 3 of 9 |
Compare
Put Scilex side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Scilex | FY25 | −46.5% | −1,143.7% | 12.2% | — | — | 3 | |
| Foghorn Therapeutics | FY25 | 36.8% | −279.5% | −278.7% | — | — | 2 | Compare |
| Verastem | FY25 | 209.1% | −550.3% | — | — | — | — | Compare |
| EyePoint | FY25 | −27.5% | −776.0% | −775.8% | — | — | — | Compare |
| Nanobiotix | FY25 | — | −33.2% | −104.2% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 24 | 31 | 38 | 47 | 57 | 30 |
| Revenue growth | — | 32.9% | 21.4% | 22.9% | 21.1% | −46.5% |
| Gross profit | 21 | 28 | 27 | 31 | 167 | — |
| Research and development | 10 | 9 | 9 | 13 | 10 | 21 |
| Operating income | −35 | −36 | −51 | −105 | −83 | −346 |
| Net income | −48 | −88 | −23 | −114 | −73 | −374 |
| Diluted EPS (US$) | −0.36 | −0.67 | −0.17 | −1.28 | −8.05 | −36.48 |
| Diluted shares (millions) | 133 | 133 | 134 | 130 | 0 | 11 |
| Cash flow | ||||||
| Cash from operations | −32 | −29 | −21 | −21 | 19 | 4 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −31 | −29 | −21 | −21 | 19 | 4 |
| Dividends paid | 0 | 0 | 0 | 9 | 9 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 5 | 6 | 5 | 15 | 16 | 16 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 0 | 5 | 2 | 4 | 3 | 5 |
| Debt incl. finance leases | — | 110 | 0 | 0 | 0 | 0 |
| Total assets | 0 | 78 | 86 | 101 | 93 | 365 |
| Total liabilities | 0 | 302 | 50 | 274 | 286 | 577 |
| Shareholders' equity | 0 | −224 | 36 | −173 | −193 | −208 |
| Margins and ratios | ||||||
| Gross margin | 90.9% | 88.4% | 71.6% | 66.5% | 295.8% | — |
| Operating margin | −149.7% | −114.4% | −133.1% | −225.6% | −147.4% | −1,143.7% |
| Net margin | −201.7% | −282.4% | −61.4% | −244.6% | −128.7% | −1,236.4% |
| Free cash flow margin | −133.6% | −91.5% | −55.9% | −44.4% | 34.2% | 12.2% |
| Rule of 40 (growth + FCF margin) | — | −58.6% | −34.5% | −21.5% | 55.3% | −34.4% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | — | — | — | — | — |
| Return on assets | — | −226.3% | −28.4% | −121.7% | −75.0% | −163.4% |
| Net debt to EBITDA | — | — | — | — | — | — |